简介 联系方式 相互作用: 118 620
根据名称进行药物检索

Ketoprofen Capsules与肝毒性

Ketoprofen Capsules与肝毒性安全配伍检测的结果。

检测结果:
Ketoprofen Capsules <> 肝毒性
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

边界线的海拔高度血清转氨酶，乳酸脫氫酶，并硷性磷酸酶已经报道了在多达15%的患者处理与非甾体抗炎药(非甾体抗炎药). 这些异常可能取得进展，仍然保持不变或倒退的持续治疗。 值得注意的肝脏酶的海拔超过3次正常上限已经报告了大约1％的患者在临床试验。 此外，罕见的情况下严重的肝毒性，包括肝坏死肝功能衰竭、黄疸病和致命的暴发性肝炎，已有报道。 治疗与药物，应给予谨慎地在患有先前存在的肝脏疾病。 定期监测的肝功能是建议在长时间的治疗。 非甾体抗炎药也是高蛋白质-能和一些有广泛代谢通过的肝脏。 新陈代谢活动和/或血浆中的蛋白质结合可以改变病人的肝功能损害。 一剂用量减少可能需要在一些情况。

来源
  • "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • Whittaker SJ, Amar JN, Wanless IR, Heathcote J "Sulindac hepatotoxicity." Gut 23 (1982): 875-7
  • Knadler MP, Brater DC, Hall SD "Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status." J Pharmacol Exp Ther 249 (1989): 378-85
  • Davies NM "Clinical pharmacokinetics of flurbiprofen and its enantiomers." Clin Pharmacokinet 28 (1995): 100-14
  • Dhand AK, LaBrecque DR, Metzger J "Sulindac (clinoril) hepatitis." Gastroenterology 80 (1981): 585-6
  • Selley ML, Madsen BW, Thomas J "Protein binding of tolmetin." Clin Pharmacol Ther 24 (1978): 694-705
  • Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans." Drug Metab Dispos 15 (1987): 618-26
  • Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR "Metabolism of nabumetone (BRL 14777) by various species including man." Xenobiotica 14 (1984): 327-37
  • Reeve PA, Moshiri M, Bell GD "Pulmonary oedema, jaundice and renal impairment with naproxen." Br J Rheumatol 26 (1987): 70-1
  • Breen EG, McNicholl J, Cosgrove E, McCabe J, Stevens FM "Fatal hepatitis associated with diclofenac." Gut 27 (1986): 1390-3
  • Chamouard JM, Barre J, Urien S, Houin G, Tillement JP "Diclofenac binding to albumin and lipoproteins in human serum." Biochem Pharmacol 34 (1985): 1695-700
  • Banks AT, Zimmerman HJ, Ishak KG, Harter JG "Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions." Hepatology 22 (1995): 820-7
  • Homon CA, Fluck ER, Janssen FW, Ruelius HW "Protein binding and clearance of oxaprozin, a highly bound anti- inflammatory agent." Agents Actions 12 (1982): 211-5
  • Hucker HB, Stauffer SC, White SD, et al "Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]-indene-3-acetic acid in the." Drug Metab Dispos 1 (1973): 721-36
  • Hepps KS, Maliha GM, Estrada R, Goodgame RW "Severe cholestatic jaundice associated with piroxicam." Gastroenterology 101 (1991): 1737-40
  • Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J "Diclofenac-associated hepatotoxicity." JAMA 264 (1990): 2660-2
  • Calvo MV, Dominguez-Gil A, Macias JG, Diez JL "Naproxen disposition in hepatic and biliary disorders." Int J Clin Pharmacol Ther Toxicol 18 (1980): 242-6
  • Rubin A, Warrick P, Wolen RL, et al "Physiological disposition of fenoprofen in man III: metabolism and protein binding of fenoprofen." J Pharmacol Exp Ther 183 (1972): 449-57
  • Jick H, Derby LE, Rodriguez LA, et al "Liver disease associated with diclofenac, naproxen, and piroxicam." Pharmacotherapy 12 (1992): 207-12
  • Ferdinandi ES, Sehgal SN, Demerson CA, Dubuc J, Zilber J, Dvornik D, Cayen MN "Disposition and biotransformation of C-etodolac in man." Xenobiotica 16 (1986): 153-66
  • Purdum PP, Shelden SL, Boyd JW, Shiffman ML "Oxaprozin-induced fulminant hepatitis." Ann Pharmacother 28 (1994): 1159-61
  • Ramakrishna B, Viswanath N "Diclofenac-induced hepatitis - case report and literature review." Liver 14 (1994): 83-4
  • Catalano MA "Worldwide safety experience with diclofenac." Am J Med 80 (1986): 81-7
  • Lee SM, O'Brien CJ, Williams R, Whitaker S, Gould SR "Subacute hepatic necrosis induced by piroxicam." Br Med J (Clin Res Ed) 293 (1986): 540-1
  • Duggan DE, Hogans AF, Kwan KC, McMahon FG "The metabolism of indomethacin in man." J Pharmacol Exp Ther 181 (1972): 563-75
  • Riess W, Stierlin H, Degen P, et al "Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren." Scand J Rheumatol Suppl 22 (1978): 17-29
  • Paterson D, Kerlin P, Walker N, et al "Piroxicam induced submassive necrosis of the liver." Gut 33 (1992): 1436-8
  • "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  • "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  • Caballeria E, Masso RM, Arago JV, Sanchis A "Piroxicam hepatotoxicity." Am J Gastroenterol 85 (1990): 898-9
  • "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  • Helleberg L "Clinical pharmacokinetics of indomethacin." Clin Pharmacokinet 6 (1981): 245-58
  • Gallanosa AG, Spyker DA "Sulindac hepatotoxicity: a case report and review." Clin Toxicol 23 (1985): 205-38
  • Brocks DR, Jamali F "Clinical pharmacokinetics of ketorolac tromethamine." Clin Pharmacokinet 23 (1992): 415-27
  • "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  • Planas R, De Leon R, Quer JC, Barranco C, Bruguera M, Gassull MA "Fatal submassive necrosis of the liver associated with piroxicam." Am J Gastroenterol 85 (1990): 468-70
  • "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Stierlin H, Faigle JW "Biotransformation of diclofenac sodium (Voltaren) in animals and man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile." Xenobiotica 9 (1979): 611-21
  • Wood LJ, Mundo F, Searle J, Powell LW "Sulindac hepatotoxicity: effects of acute and chronic exposure." Aust N Z J Med 15 (1985): 397-401
  • Julh RP, Van Thiel DH, Dittert LW, et al "Ibuprofen and sulindac kinetics in alcoholic liver disease." Clin Pharmacol Ther 34 (1983): 104-9
  • Pages LJ, Martinez JJ, Garg DC, et al "Pharmacokinetics of ketorolac tromethamine in hepatically impaired vs young healthy subjects." J Clin Pharmacol 27 (1987): 724
  • O'Brien WM, Bagby GF "Rare adverse reactions to nonsteroidal antiinflammatory drugs." J Rheumatol 12 (1985): 562-7
  • Gerber D "Adverse reactions of piroxicam." Drug Intell Clin Pharm 21 (1987): 707-10
  • Macdonald JI, Wallace SM, Mahachai V, Verbeeck RK "Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis." Eur J Clin Pharmacol 42 (1992): 471-4
  • Victorino RM, Baptista A, Silveira JC, de Moura MC "Jaundice associated with naproxen." Postgrad Med J 56 (1980): 368-70
  • Sallie RW, McKenzie T, Reed WD, Quinlan MF, Shilkin KB "Diclofenac hepatitis." Aust N Z J Med 21 (1991): 251-5
  • Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW "Metabolism and kinetics of oxaprozin in normal subjects." Clin Pharmacol Ther 27 (1980): 352-62
  • Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ "Fulminant hepatic failure associated with etodolac use." Am J Gastroenterol 90 (1995): 659-61
  • Cappell MS, Kozicky O, Competiello LS "Indomethacin-induced cholestasis." J Clin Gastroenterol 10 (1988): 445-7
  • Brocks DR, Jamali F "Etodolac clinical pharmacokinetics." Clin Pharmacokinet 26 (1994): 259-74
  • Maleev A, Vlahov V, Gruev I, Dierdorf D, Kostova N, Bacracheva N "Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone." Int J Clin Pharmacol Ther Toxicol 24 (1986): 425-9
  • Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG "The pharmacokinetics of diclofenac sodium following intravenous and oral administration." Eur J Clin Pharmacol 16 (1979): 405-10
  • Williams RL, Upton RA, Cello JP, et al "Naproxen disposition in patients with alcoholic cirrhosis." Eur J Clin Pharmacol 27 (1984): 291-6
  • Selley ML, Glass J, Triggs EJ, Thomas J "Pharmacokinetic studies of tolmetin in man." Clin Pharmacol Ther 17 (1975): 599-605
  • "Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
  • Giroux Y, Moreau M, Kass TG "Cholestatic jaundice caused by sulindac." Can J Surg 25 (1982): 334-5
  • "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  • Klein SM, Khan MA "Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy." J Rheumatol 10 (1983): 513-3
  • Schattenkirchner M "An updated safety profile of etodolac in several thousand patients." Eur J Rheumatol Inflamm 10 (1990): 56-65
  • "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  • Stierlin H, Faigle JW, Sallmann A, et al "Biotransformationm of diclofenac sodium (Voltaren) in animal and in man. I. Isolation and identification of principal metabolites." Xenobiotica 9 (1979): 601-10
  • Lockwood GF, Albert KS, Szpunar GJ, Wagner JG "Pharmacokinetics of ibuprofen in man III: plasma protein binding." J Pharmacokinet Biopharm 11 (1983): 469-82
  • Hyneck ML, Smith PC, Munafo A, et al "Disposition and irreversible plasma protein binding of tolmetin in humans." Clin Pharmacol Ther 44 (1988): 107-14
  • "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  • Lewellen OR, Templeton R "The pharmacokinetics of ketoprofen in man during and after repeated oral dosing (50mg q.i.d.) with orudis." Scand J Rheumatol 14 (1976): 53-62
  • Hyson CP, Kazakoff MA "A severe multisystem reaction to sulindac." Arch Intern Med 151 (1991): 387-8
  • Verbeeck RK, Richardson CJ, Blocka KL "Clinical pharmacokinetics of piroxicam." J Rheumatol 13 (1986): 789-96
  • Scully LJ, Clarke D, Barr RJ "Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis." Dig Dis Sci 38 (1993): 744-51
  • Bhogaraju A, Nazeer S, AlBaghdadi Y, Rahman M, Wrestler F, Patel N "Diclofenac-associated hepatitis." South Med J 92 (1999): 711-3
  • "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  • Turner R "Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis." Semin Arthritis Rheum 17 (1988): 29-35
  • Purcell P, Henry D, Melville G "Diclofenac hepatitis." Gut 32 (1991): 1381-5
  • Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
  • Alvan G, Orme M, Bertilsson L, et al "Pharmacokinetics of indomethacin." Clin Pharmacol Ther 18 (1975): 364-73
  • "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  • "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  • Sherman KE, Jones C "Hepatotoxicity associated with piroxicam use." Gastroenterology 103 (1992): 354-5
  • Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
  • "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.
  • Park GD, Spector R, Headstream T, Goldberg M "Serious adverse reactions associated with sulindac." Arch Intern Med 142 (1982): 1292-4
  • "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  • "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  • "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  • "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Blouin R, Chaudhary I, Nishihara K, Cox S "The effects of liver and renal disease on stereoselective serum binding of flurbiprofen." Br J Clin Pharmacol 35 (1993): 62-4
  • Hyneck ML "An overview of the clinical pharmacokinetics of nabumetone." J Rheumatol 19 (1992): 20-4
  • Richardson CJ, Blocka KL, Ross SG, Verbeeck RK "Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam." Eur J Clin Pharmacol 32 (1987): 89-91
  • Daniele B, Pignata S, D'Agostino L, et al "Sulindac-induced severe hepatitis." Am J Gastroenterol 83 (1988): 1429-31
  • Hvidberg E, Lausen HH, Jansen JA "Indomethacin: plasma concentrations and protein binding in man." Eur J Clin Pharmacol 4 (1972): 119-24
  • Zimmerman HJ "Hepatic effects of oxaprozin." Semin Arthritis Rheum 15 (1986): 35-9
  • Lasseter K, Shamblen E, Murdoch A, Marino M, Minor M, Kraml MJ "Pharmacokinetics of etodolac in patients with hepatic cirrhosis." J Clin Pharmacol 28 (1988): 933
Ketoprofen Capsules

非专利名称: ketoprofen

品牌: Oruvail, Orudis, Actron, Orudis KT

同义词: Ketoprofen

Ketoprofen Capsules是什么？
其他的药物 删除
公认药物相互作用的清单
DiseDoc 和平
与食物，生活方式相互作用
  1. Ketoprofen Capsules
药物互相作用
  1. Ketoprofen Capsules
我们使用Cookie来优化网站性能。通过继续浏览这个网站,你同意使用Cookie。 同意